Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (November 2016)

31 slides from Zynerba Pharmaceuticals's investor presentation, Nov 16, 2016

  1. Slide 1: Disclaimer

    Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,

  2. Slide 2: Company Highlights

    Company Highlights 3 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory

  3. Slide 3: Robust Pipeline

    Robust Pipeline 4 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 NDA Filing ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epilepsy in Adults with Focal Seizures Osteoarthritis Fragile X Syndrome (US FDA Orphan

  4. Slide 4: Multiple Near-term Milestones Expected

    Multiple Near-term Milestones Expected 5 ZYN001 THC Pro-Drug Patch ZYN002 CBD Gel Epilepsy in Adults with Focal Seizures Osteoarthritis Fragile X Syndrome (Orphan Drug Designation) Fibromyalgia Peripheral Neuropathic Pain STOP Dosing September Phase 2 Initiation Phase 2 Top Line Results STOP Top Lin

  5. Slide 5: ZYN002 – CBD Gel

    ZYN002 – CBD Gel First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 6 CBD Delivery

  6. Slide 6: Transdermal ZYN002 vs. Oral CBD

    Transdermal ZYN002 vs. Oral CBD 7 Potential Benefits of Transdermal ZYN002 vs. Oral CBD More consistent, controlled and sustained plasma level Avoids first-pass metabolism in the liver Fewer drug-drug interactions Avoids the GI tract Very low incidence of gastrointestinal events Avoids degradation o

  7. Slide 7: Transdermal CBD Avoids Degradation of CBD to THC

    Transdermal CBD Avoids Degradation of CBD to THC 8 In Vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publis

  8. Slide 8: ZYN002 Phase 1 Trials Summary

    Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well-tolerated at all dose

  9. Slide 9: Why Are We Studying CBD in Epilepsy in Adults?

    Why Are We Studying CBD in Epilepsy in Adults? 10 * Hauser WA Epilepsia. 4):S6-S14, 1992 CBD is effective in multiple animal models of epilepsy, which are highly predictive of efficacy in humans Kindling and maximal electroshock (models for focal and generalized seizures) Audiogenic, penicillin, pen

  10. Slide 10: ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy

    ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy 11 Lennox-Gastaut Syndrome Dravet Syndrome Refractory Epilepsy with Focal Seizures Patient Age 2 – 55 years old 2 – 18 years old 18 – 70 years old Brain Localization Multi-Foci Multi-Foci One or More Foci Seizure Type(s) Focal Ton

  11. Slide 11: Epilepsy Phase 2 Clinical Trials – STAR 1 and STAR 2

    Epilepsy Phase 2 Clinical Trials – STAR 1 Initiated June 2016; STAR 2 Initiated in November 2016 12 ZYN002 High Dose: 195 mg of CBD 4.2% gel every 12 hours for 12 weeks ZYN002 Low Dose: 97.5 mg of CBD 4.2% gel every 12 hours for 12 weeks Placebo every 12 hours for 12 weeks 8-week baseline period to

  12. Slide 12: Why ZYN002 in Osteoarthritis?

    Why ZYN002 in Osteoarthritis? 13 CBD modulates the vanilloid TRPV1 receptor which mediates antinociceptive and anti-inflammatory effects Mono-arthritic rat model provides proof of concept* ZYN002 was applied for four days after inducing arthritis in rats Significant reductions in: Swelling of knee j

  13. Slide 13: Osteoarthritis Phase 2 Clinical Trial – STOP

    Osteoarthritis Phase 2 Clinical Trial – Initiated August 2016 14 ZYN002 High Dose: 250 mg of CBD 4.2% gel every 12 hours for 12 weeks ZYN002 Low Dose: 125 mg of CBD 4.2% gel every 12 hours for 12 weeks Placebo every 12 hours for 12 weeks 1-week Washout Period; 1-week Baseline Period STOP (Synthetic

  14. Slide 14: What is Fragile X Syndrome?

    What is Fragile X Syndrome? 15 Fragile X Syndrome Autism spectrum disorder Most common inherited intellectual disability Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogeno

  15. Slide 15: Why ZYN002 in Fragile X Syndrome?

    Why ZYN002 in Fragile X Syndrome? CBD may effectively treat Fragile X syndrome In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong anxiolyti

  16. Slide 16: Fragile X Syndrome Phase 2 Clinical Trial

    Fragile X Syndrome Phase 2 Clinical Trial – Initiation Expected in 2H16 Open-label trial enrolling 16 patients aged 5 – 17 years old 12 weeks of dosing Outcome measures Anxiety, Depression and Mood Scale in FXS Aberrant Behavior Checklist Visual analog scale (VAS) for hyperactivity/impulsivity 17

  17. Slide 17: ZYN001 – THC Pro-Drug Patch

    ZYN001 – THC Pro-Drug Patch 18 Patent-protected synthetic D-glyceric acid ester-Δ9-tetrahydrocannabinol in a transdermal patch Working with LTS Lohmann Therapie-Systeme AG to optimize the formulation of ZYN001 for use in a state of the art drug-adhesive matrix transdermal patch before initiating pha

  18. Slide 18: Why a Patch?

    Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 19 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro

  19. Slide 19: Why THC in Fibromyalgia?

    THC is a CB1 agonist Has an analgesic effect in chronic pain models Acts at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=40) — significant decreases in pain scores on multip

  20. Slide 20: THC in Peripheral Neuropathic Pain

    THC’s agonist effect on CB1 receptors modulates nociceptive thresholds by regulating neuronal activity Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN

  21. Slide 21: ZYN001 – THC Pro-Drug Patch Status

    ZYN001 – THC Pro-Drug Patch Status In vitro and in vivo studies to date show: Effective skin permeation with sustained delivery Non-mutagenic and non-genotoxic Safety pharmacology GLP studies Profile similar to THC GLP toxicology studies ongoing Working with LTS to optimize to a state of the art dru

  22. Slide 22: ZYN001 Preliminary Phase 1 Clinical Plan

    ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan 23 Trial Patients Dosing PD Evaluations Timing Single Rising Dose Trial in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with fibromyalgia Single dose Cognition and attention (Tr

  23. Slide 23: ZYN001 Preliminary Phase 2 Clinical Plan

    24 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna

  24. Slide 24: Cash Expected to Fund 5 Phase 3 Ready Programs

    25 IPO August 2015 (NASDAQ: ZYNE) raised $42.1million, net Raised $9.5 million in net proceeds from the sale and issuance of 753,799 common shares through ATM from September 16 – November 11, 2016 at an average selling price of $13.38 Cash as of September 30, 2016 $31.8; no debt Includes $5.3 millio

  25. Slide 25: A Compelling Investment Opportunity

    A Compelling Investment Opportunity – Why Zynerba Could be the Next Explosive Growth Cannabinoid Company 26 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in redu

  26. Slide 26: Proven Leadership in Transdermal Drug Development

    Proven Leadership in Transdermal Drug Development 27 Armando Anido Chairman of the Board & Chief Executive Officer Terri Sebree President Jim Fickenscher CFO & VP Corp. Development Donna Gutterman, PharmD VP, Medical Nancy Tich, PhD VP, Clinical

  27. Slide 27: Scientific Advisors

    Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M

  28. Slide 28: Company Highlights

    Company Highlights 29 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory

  29. Slide 29: Investor Relations

    Investor Relations 30 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Canaccord Genuity: Arlinda Lee, PhD Oppenheimer: Marcus Ho Roth: Michael Higgins H.C. Wainwright: Corey Davis, PhD * Note: Any opinions, estimates or forecasts regarding Zynerba Phar

  30. Slide 30: November 2016

    November 2016 A clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs

  31. Slide 31: Aclini ialty pharmaceutical

    Aclini ialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs November 2016

Zynerba Pharmaceuticals — Investor Presentation (November 2016) on 6ix